The best hair loss treatment for women depends on the underlying cause — and getting that diagnosis right is the essential first step. Hair loss affects millions of women in the UK, yet many delay seeking help, unaware that effective, evidence-based options exist. From female pattern hair loss and telogen effluvium to autoimmune and hormonal conditions, the causes are varied and the treatments differ significantly. This guide covers clinically evidenced treatments recommended by NHS and NICE guidance, prescription options, lifestyle factors, and when to seek specialist input — helping you make informed decisions about your hair health.

Common Causes of Hair Loss in Women

Female pattern hair loss (androgenetic alopecia) is the most common cause, but telogen effluvium, iron deficiency, thyroid disorders, PCOS, and scarring alopecias are also frequent contributors requiring targeted investigation.

Hair loss in women is more common than many people realise, affecting millions of women in the UK at any one time. Understanding the underlying cause is essential before considering any treatment, as the most effective approach will depend entirely on what is driving the hair loss in the first place.

The most frequently diagnosed condition is female pattern hair loss (FPHL), also known as androgenetic alopecia. This is a genetically influenced, hormone-related condition characterised by gradual thinning across the crown and top of the scalp. The frontal hairline is often preserved, though patterns can vary and some women do experience frontal thinning. It can begin at any age but becomes increasingly common after the menopause.

Other common causes include:

• Telogen effluvium — a temporary, diffuse shedding often triggered by physical or emotional stress, childbirth, rapid weight loss, surgery, or illness (including post-viral conditions)

• Iron deficiency — low ferritin (iron stores) is one of the most common and correctable contributors to hair shedding in women of reproductive age; other nutritional factors such as vitamin D, zinc, or B12 deficiency may also play a role, though testing should be targeted to clinical risk rather than performed routinely

• Thyroid disorders — both hypothyroidism and hyperthyroidism can cause diffuse hair thinning

• Polycystic ovary syndrome (PCOS) — elevated androgens can accelerate hair follicle miniaturisation

• Alopecia areata — an autoimmune condition causing patchy hair loss

• Traction alopecia — caused by prolonged tension from tight hairstyles

• Scarring alopecias — conditions such as lichen planopilaris, frontal fibrosing alopecia, and central centrifugal cicatricial alopecia (CCCA) cause permanent follicle destruction if not treated promptly; these require urgent referral to a dermatologist

Certain medications — including anticoagulants, antidepressants, and some hormonal contraceptives — may contribute to hair shedding in some individuals. If you suspect a medicine is causing hair loss, do not stop taking it without first speaking to your prescriber, as this could be harmful. A thorough medical history and appropriate investigations are the essential first step in identifying the correct diagnosis and guiding treatment decisions.

Sources: NHS Hair Loss overview; NICE CKS Androgenetic alopecia; PCDS Female pattern hair loss guidance; BAD patient information on female pattern hair loss.

When to See a GP or Specialist About Hair Loss

See your GP promptly if hair loss is sudden, patchy, accompanied by scalp symptoms, or associated with systemic symptoms such as fatigue or menstrual irregularity; urgent dermatology referral is needed if scarring alopecia is suspected.

Many women delay seeking medical advice about hair loss, often attributing it to normal ageing or stress. However, early assessment is important, as some causes are readily treatable and prompt intervention can help limit further loss and support regrowth.

You should make an appointment with your GP if you notice:

• Sudden or rapid hair shedding over a short period

• Patchy or irregular hair loss rather than diffuse thinning

• Hair loss accompanied by scalp symptoms such as itching, scaling, redness, tenderness, or pain

• Associated symptoms such as fatigue, weight changes, irregular periods, acne, or hirsutism — which may suggest an underlying hormonal or thyroid condition

• Hair loss following a new medication

• Significant psychological distress affecting daily life or wellbeing

Seek prompt or urgent dermatology referral if there are features suggesting a scarring alopecia — such as perifollicular redness or scaling, scalp tenderness, rapid progression, or loss of follicular openings on close inspection. Scarring alopecias can cause permanent hair loss if not treated early.

Your GP will typically begin with a clinical examination and a targeted blood panel. This commonly includes a full blood count (FBC), ferritin, and thyroid function tests (TFTs). Androgen levels (including testosterone and DHEAS) should be checked when there are clinical features of hyperandrogenism — such as hirsutism, acne, menstrual irregularity, or signs of virilisation — rather than routinely. Vitamin D, zinc, and B12 testing should similarly be guided by clinical risk factors or symptoms rather than performed as a matter of course.

If the diagnosis remains unclear, or if the hair loss is severe or unresponsive to initial management, your GP may refer you to a consultant dermatologist with a specialist interest in hair disorders. In some cases, a scalp biopsy may be recommended to confirm the diagnosis histologically. NHS dermatology waiting times can be lengthy, and some women choose to access private dermatology services in the interim. If seeking private input, prioritise a GMC-registered consultant dermatologist; if considering a trichologist, be aware that trichology is not a statutorily regulated profession in the UK, so verify the practitioner's qualifications carefully. Regardless of the route, professional assessment should always precede the use of any treatment — including over-the-counter products — to ensure the approach is appropriate and safe.

Sources: NICE CKS Alopecia areata; NICE CKS Androgenetic alopecia; PCDS Hair loss referral and investigation guidance; BAD scarring alopecia guidance; NHS Hair Loss overview.

NHS-Recommended and Clinically Evidenced Treatments

Topical minoxidil is the only UK-licensed treatment for female pattern hair loss; baricitinib is NICE-recommended for severe alopecia areata, and telogen effluvium is managed by treating the underlying cause.

The treatment landscape for female hair loss has expanded considerably in recent years, though it is important to distinguish between interventions with robust clinical evidence and those with limited or anecdotal support. NICE and NHS guidance currently focuses primarily on treatments for female pattern hair loss and alopecia areata, as these are the most prevalent conditions presenting in clinical practice.

Minoxidil remains the only topical treatment licensed in the UK specifically for female pattern hair loss. The 2% topical solution is licensed for women; certain 5% foam formulations are also licensed for use in women in the UK — always check the specific product's Summary of Product Characteristics (SmPC) and directions before use. According to the product SmPC, the exact mechanism by which minoxidil promotes hair growth is not fully understood, though it is thought to prolong the anagen (growth) phase of the hair cycle and may enlarge miniaturised follicles. Clinical trials consistently demonstrate that regular use leads to a reduction in shedding and modest but measurable regrowth in the majority of women who use it consistently. It must be applied to a dry scalp as directed and continued long-term — stopping treatment typically results in a return to baseline shedding within several months.

For alopecia areata, NICE published a Technology Appraisal in 2023 recommending baricitinib (a JAK inhibitor, brand name Olumiant®) for severe alopecia areata in adults. Eligibility requires a Severity of Alopecia Tool (SALT) score of 50 or above (i.e., 50% or more scalp hair loss), and treatment must be initiated and supervised by a specialist dermatologist. Treatment should be stopped if there is no adequate response after 36 weeks. Important safety considerations include an increased risk of serious infections, venous thromboembolism (VTE), and major adverse cardiovascular events (MACE); baricitinib is contraindicated in pregnancy and effective contraception is required. The MHRA has issued updated safety advice for the JAK inhibitor class. For patchy alopecia areata, intralesional corticosteroid injections administered by a dermatologist remain a standard option. Topical immunotherapy (e.g., diphencyprone) may be considered in specialist centres for more extensive disease.

For telogen effluvium, treatment is primarily directed at the underlying trigger — correcting confirmed nutritional deficiencies, managing thyroid disease, or addressing psychological stress. In most cases, hair density recovers naturally within six to twelve months once the precipitating cause is resolved.

Sources: MHRA/eMC SmPC: Regaine for Women 2% Cutaneous Solution; MHRA/eMC SmPC: Regaine for Women Once A Day 5% Foam; NICE Technology Appraisal: Baricitinib for severe alopecia areata (2023); MHRA Drug Safety Update: JAK inhibitors; NICE CKS Alopecia areata; EMA EPAR: Olumiant (baricitinib).

Prescription Options Available in the UK

Oral minoxidil, spironolactone, and co-cyprindiol are available on prescription for female hair loss but are used off-licence; finasteride is contraindicated in women of childbearing potential and not licensed for women in the UK.

Beyond over-the-counter minoxidil, several prescription treatments are available in the UK for women with hair loss. It is important to note that many are used off-licence and should only be initiated under medical supervision following appropriate assessment.

Oral minoxidil at low doses (typically 0.5–2.5 mg daily) has gained considerable interest as an alternative to topical application, particularly for women who find topical formulations inconvenient or who experience scalp irritation. Emerging evidence, including data published in the British Journal of Dermatology, suggests it is effective and generally well tolerated at low doses. However, it is currently prescribed off-licence in the UK and requires careful patient selection. Before starting, a cardiovascular history should be taken and baseline blood pressure and heart rate recorded; ongoing monitoring of these parameters is recommended. Caution is required in women taking other antihypertensive medicines. Potential side effects include unwanted facial or body hair (hypertrichosis), fluid retention, oedema, and tachycardia; rarely, more significant cardiovascular effects may occur. Oral minoxidil should be avoided in pregnancy and during breastfeeding.

Anti-androgen therapies may be considered in women with FPHL or hair loss associated with PCOS and confirmed elevated androgen levels. Options include:

• Spironolactone (off-licence for hair loss) — an aldosterone antagonist with anti-androgenic properties, commonly used at doses of 50–200 mg daily. Baseline and periodic monitoring of urea and electrolytes (U&Es) is required due to the risk of hyperkalaemia. It should be avoided in renal impairment and other states predisposing to hyperkalaemia. Effective contraception is essential, as spironolactone is contraindicated in pregnancy.

• Co-cyprindiol (e.g., Dianette®) — a combined oral contraceptive licensed for severe acne and hirsutism in women; its use for hair loss is off-licence. It carries an increased risk of venous thromboembolism (VTE) compared with standard combined oral contraceptives, and individual risk factors should be assessed before prescribing. Duration of use should be limited in line with current MHRA guidance.

Finasteride, a 5-alpha reductase inhibitor widely used in men, is not licensed for use in women in the UK and is contraindicated in women of childbearing potential due to the risk of feminisation of a male foetus. Women must not handle crushed or broken finasteride tablets. It may occasionally be considered post-menopause under specialist supervision only, with full discussion of the off-licence status and potential adverse effects.

All prescription treatments should be reviewed regularly, with monitoring for side effects and treatment response. If you experience a suspected side effect from any medicine or supplement, you can report it to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk or through the Yellow Card app.

Sources: BNF monographs: Minoxidil (oral/topical), Spironolactone, Co-cyprindiol, Finasteride; MHRA/eMC SmPC: Loniten (minoxidil tablets); MHRA/eMC SmPC: Co-cyprindiol; MHRA Drug Safety Update: Co-cyprindiol — VTE risk; MHRA/eMC SmPC: Finasteride 5 mg.

Lifestyle, Nutrition and Supportive Measures

Correcting confirmed nutritional deficiencies — particularly iron — is the most evidence-based lifestyle intervention; supplements should only be taken following blood test confirmation of deficiency, not empirically.

Whilst medical treatments form the cornerstone of managing significant hair loss, lifestyle factors and nutritional status play a meaningful supporting role — and in some cases, addressing these alone may be sufficient to restore normal hair cycling.

Nutritional optimisation is particularly important. Iron deficiency is one of the most common and correctable contributors to hair shedding in women of reproductive age. Low ferritin has been associated with increased shedding in some studies, though the precise threshold at which treatment is beneficial remains debated; ferritin results should always be interpreted alongside a full blood count and, where relevant, inflammatory markers (CRP), in line with UK primary care guidance. Supplementation should be guided by blood test results and clinical assessment rather than taken empirically. Dietary sources of iron include red meat, legumes, dark leafy vegetables, and fortified cereals; absorption of non-haem iron is enhanced by consuming vitamin C at the same time.

Vitamin D, zinc, and B12 may also contribute to hair health when genuinely deficient, but supplementation should only follow confirmed deficiency — routine or empirical supplementation is not generally recommended. Ensuring adequate dietary protein also supports healthy follicle function. Important note on biotin: high-dose biotin supplements can interfere with a range of laboratory tests, including thyroid function tests and troponin assays, potentially producing misleading results. If you are taking biotin supplements, inform your clinician before any blood tests are taken. This is an MHRA-recognised safety concern.

Scalp and hair care practices can support hair health as comfort and cosmetic measures, though their direct impact on hair regrowth is limited:

• Avoid excessive heat styling, bleaching, or chemical processing, which can weaken the hair shaft

• Use gentle shampoos and avoid vigorous towel-drying

• Minimise tight hairstyles such as high ponytails, braids, or extensions that place traction on the follicle

• Regular, gentle scalp massage may modestly improve blood flow to follicles, though evidence remains limited

Psychological wellbeing should not be overlooked. Hair loss can have a profound impact on self-esteem and quality of life. Cognitive behavioural therapy (CBT), peer support groups, and organisations such as Alopecia UK offer valuable resources. The NHS also provides access to psychological support through GP referral where distress is significant.

Finally, whilst the market is saturated with hair supplements and topical serums making bold claims, most lack robust clinical evidence. Supplements are only likely to benefit those with a confirmed deficiency. Always discuss new supplements or treatments with a healthcare professional before starting.

Sources: PCDS Female pattern hair loss and Telogen effluvium — iron/ferritin advice; NHS Vitamins and minerals guidance; MHRA Drug Safety Update: Biotin interference with laboratory tests; NICE CKS Telogen effluvium.

Frequently Asked Questions